Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection

Author： Wilke Russell A  

Publisher： Future Medicine

ISSN： 1741-0541

Source： Personalized Medicine, Vol.3, Iss.4, 2006-11, pp. : 385-390

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Question‐Based Approach to Adopting Pharmacogenetics to Understand Risk for Clinical Variability in Pharmacokinetics in Early Drug Development

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 291-295

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice

By Wilke Russell A   Musana A Kenneth   Weber Wendell W  

Personalized Medicine, Vol. 2, Iss. 3, 2005-08 ,pp. : 213-224

Future Medicine

Access to resources Recommend Favorite

Development of a Fuzzy Logic-based Model for Monitoring Cardiovascular Risk

By  

International Journal of Healthcare Information Systems and Informatics (IJHISI), Vol. 10, Iss. 4, 2015-10 ,pp. : 38-55

IGI Global_journal

Access to resources Recommend Favorite

Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 189-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Functional Gene Variants of CYP3A4

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 340-348

John Wiley & Sons Inc

Access to resources Recommend Favorite